Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

NCT05622175 | Withdrawn Phase 1 DMC

• 1 other identifier: PH-F8IL10INTRA-02/22
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This multicenter, prospective Phase I study is aimed at testing the safety of F8IL10 via i.a. administration once every 4 weeks over 8 weeks in patients with RA who, despite treatment with stable doses (at least 3 months) of DMARDs (conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for i.a. injections.

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (2)

• MTD

  Maximum Tolerated Dose (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level.

  From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

• RD

  Recommended Dose (in dose escalation part). The RD is defined by the Data Safety Monitoring Board (DSMB) among the safely tested dose level (i.e. not exceeding the MTD) considering the overall results dataset (e.g. safety, tolerability, efficacy, immunogenicity, pharmacokinetics) obtained in this study.

  From the enrollment of each patient until the completion of the treatment (for a maximum of 9 weeks)

Secondary Outcomes (11)

• Safety and Tolerability

  From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

• Efficacy measured as improvement in visual analogue scale for involved joint pain (jVAS)

  From the start of treatment period (for a maximum of 9 weeks) to the end of follow-up period (for a maximum of 6 months)

• Quality of life - Collection of HAQ-DI for the evaluation of physical function

  At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

• Quality of life - Collection of SF-36 for the evaluation of overall health status

  At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

• Quality of life - Collection of FACIT-F for the evaluation of self-reported fatigue and its impact upon daily activities and function

  At day 1 and 29 (F8IL10 administration) to the end of follow-up period (for a maximum of 6 months)

Study Arms (1)

Drug: F8IL10

EXPERIMENTAL

Overall, 32 patients will participate in case no DLT would occur. 1. In the standard 3+3 dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of F8IL10 (from 0.5 to 10 mg) in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 3 patients with escalating doses of F8IL10 until the MAD is reached and won't exceed 10 mg dose level. In case a DLT would be detected, further 3 patients will be enrolled for that cohort in order to confirm the MAD or to proceed with the next dose level. Therefore, up to 30 patients could be enrolled in the dose escalation part. 2. Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level (patients treated at the RD in the course of the dose escalation phase will contribute to the total sample size).

Drug: F8IL10

Interventions

F8IL10 DRUG

The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular. Patients with arthritis flare(s) in "large joints" (shoulders, elbows, knees and ankles, with the exception of hip) and "small joints" (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per "2010 Rheumatoid Arthritis Classification Criteria" \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below: Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10

Also known as: Dekavil

Drug: F8IL10

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged ≥18 and ≤ 80 years.
• Diagnosis of RA according to ACR/EULAR classification criteria (2010) with a disease duration exceeding 6 months.
• Presence of at least an arthritis flare suitable for i.a. injection despite treatment with stable doses (for at least 3 months) of DMARDs (conventional, biologic and targeted synthetic) background therapy.
• Stable regimens of NSAIDs and/or oral corticosteroid (≤ 10 mg/day; prednisone equivalent) for a period ≥ 2 weeks prior to screening.
• All acute toxic effects of any prior therapy must have returned to classification "mild" according to CTCAE v.5.0 (published on November 27, 2017).
• Sufficient hematologic, liver and renal function:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥100 x109/L, haemoglobin (Hb) ≥ 10.0 g/dL.
• Alkaline phosphatase (AP), alanine aminotransferase (ALT) and or aspartate aminotransferase (AST) ≤ 3 x upper limit of normal range (ULN), and total bilirubin ≤ 2.0 mg/dl (34.2 µmol/L).
• Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 50 mL/min.
• Documented negative TB test (e.g. Quantiferon or equivalent) and Chest X-ray. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active TB by the study physician.
• Documented negative test for HIV-HBV-HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no ongoing infection are eligible. Results of tests carried out prior to the participation in the study may be accepted, if deemed as appropriate to exclude active infections by the study physician.
• Sexually active male or female patients of childbearing potential are eligible providing that:
• Female:
• Women of childbearing potential (WOCBP) have a negative pregnancy test performed within 14 days prior to treatment start.
• WOCBP agree to use, from the screening to 6 months following the last study drug administration, effective method of birth control as applicable per local law that both results in a Pearl index \< 1 and considered highly effective as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the "Clinical Trial Facilitation Group" (e.g. combined estrogen and progestogen containing hormonal contraception, progestogen-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, vasectomized partner, total sexual abstinence or bilateral tubal occlusion).

You may not qualify if:

• Patients must not be enrolled into the study if, at the time of enrollment, they have any of the following:
• Presence of active infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or would interfere with the study objectives or conduct.
• Pregnancy, lactation or unwillingness to use adequate contraceptive methods.
• Diagnosis of any other inflammatory arthritis or active autoimmune diseases other than RA.
• Received intra-articular administration of corticosteroids/DMARDs (for other reasons than the current study) within 4 weeks or 5 half-lives prior to the first dose of study drug, whichever is longer.
• History or currently active primary or secondary immunodeficiency.
• Concurrent malignancy or history of malignancy (except in situ melanoma) from which the patient has been disease-free for less than 2 years.
• History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
• Treatment with warfarin or other coumarin derivatives.
• Clinically significant cardiac arrhythmias or requiring permanent medication.
• Abnormal LVEF or any other abnormalities observed during baseline ECG and echocardiogram investigations that are considered as clinically significant by the investigator; subjects with current or a history of QT/QTc prolongation.
• Uncontrolled hypertension.
• Known arterial aneurism at high risk of rupture.
• Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
• Severe diabetic retinopathy.

Sponsors & Collaborators

• Philogen S.p.A.: lead

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular. A standard 3+3 dose escalation design from 0.5 to 10 mg of F8IL10 until the first instance of a DLT in the observation period from Day 1 to Day 28. In the absence of DLTs, such dose increase will continue until the MAD level is reached and won't exceed 10 mg dose level. With the occurrence of a DLT, the same dose level cohort will be expanded to 6 patients and, if additional DLTs do not occur, the dose escalation will continue to the next dose level. When two DLTs are recorded in the same dose level, MAD is automatically reached. The RD will be then defined by the DSMB .

Study Record Dates

• First Submitted: November 3, 2022
• First Posted: November 18, 2022
• Study Start: March 31, 2023
• Primary Completion: December 31, 2025
• Study Completion (Estimated): December 31, 2026
• Last Updated: December 2, 2025

Record last verified: 2025-11